Aziz Nazha, MD, discusses the potential role of ropeginterferon alfa-2b in polycythemia vera.
Aziz Nazha, MD
Advertisement
Articles by Aziz Nazha, MD
Aziz Nazha, MD, discusses the risk of progression to myelofibrosis in patients with polycythemia vera.
Aziz Nazha, MD, hematologist, Leukemia Program at the Cleveland Clinic, Taussig Cancer Institute, discusses results of a mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).
Advertisement
Latest Updated Articles
Dr. Nazha on the Risk of Progression to Myelofibrosis in Polycythemia VeraPublished: October 9th 2020 | Updated:
Dr. Nazha on the Potential Role of Ropeginterferon Alfa-2b in Polycythemia VeraPublished: October 14th 2020 | Updated:
Dr. Nazha on Mutational Model to Predict Response to Hypomethylating Agents in MDSPublished: October 7th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5